Ankur
Joint Managing Director and CEO
Notable Quotes
We have started with Stellon Biotech, our US subsidiary, to drive marketing, distribution and commercialization of our products in the US, creating a direct commercial footprint.
While FY26 is expected to remain below our historical averages, we anticipate that FY27 and beyond will reflect a normalization in performance.